Pharmaceuticals

Oral Biologics & Biosimilars Market Forecast Highlighting Key Trends And Expansion Potential

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Oral Biologics & Biosimilars Market In 2026 And 2030?

The oral biologics & biosimilars market has seen substantial growth over recent years. Its valuation is set to rise from $9.37 billion in 2025 to $11.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. This historical expansion can be attributed to several factors, including the limited availability of oral biologics, the high cost of biologic therapies, the prevailing reliance on injectable formulations, the increasing prevalence of chronic diseases, and the expanding networks of hospital and retail pharmacies.

The oral biologics & biosimilars market size is projected to experience substantial growth in the upcoming years. By 2030, its size is anticipated to reach $24.69 billion, expanding at a compound annual growth rate (CAGR) of 21.6%. This expansion during the projection period stems from factors such as the advancement of biosimilars and combination treatments, the broadening of oral biologics pipelines, a greater patient inclination towards oral drugs, the increased utilization of digital adherence tools, and improved government backing along with reimbursement frameworks. Key trends expected over this period encompass a surge in the uptake of oral biologics and biosimilars for long-term illnesses, an increase in precision therapies targeting conditions like diabetes, arthritis, and cancer, the accelerated creation of oral treatments utilizing monoclonal antibodies, the widening of distribution networks through hospitals, retail outlets, and online pharmacies, and an emphasis on patient compliance and tailored therapeutic approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Strong Drivers Are Impacting The Oral Biologics & Biosimilars Market Growth?

The increasing occurrence of chronic illnesses is anticipated to drive the expansion of the oral biologics and biosimilar market in the future. These conditions are defined as persistent health issues that usually develop gradually, including conditions like diabetes, cardiovascular diseases, and respiratory disorders. Sedentary lifestyles are a major contributor to the increase in chronic diseases, given that extended periods of physical inactivity elevate the risk of obesity, heart disease, type 2 diabetes, and certain cancers. In this context, oral biologics and biosimilars facilitate this trend by offering more accessible, economical, and user-friendly treatment alternatives for individuals handling chronic conditions. As an illustration, data from January 2023, released by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, showed that in 2023, 76.4% of U.S. adults (approximately 194 million people) indicated they had at least one chronic condition. The prevalence rates were 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the growing incidence of chronic diseases is propelling the expansion of the oral biologics and biosimilar market.

What Segment Categories Shape The Oral Biologics & Biosimilars Market Segment Landscape?

The oral biologics & biosimilars market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies

2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases

3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators

2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants

3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands

4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

What Trends Are Influencing The Evolution Of The Oral Biologics & Biosimilars Market?

Leading companies within the oral biologics & biosimilars market are concentrating on developing innovative solutions, such as specialized smart capsule development services, to enhance the oral delivery of biologics, boost bioavailability, and provide a more patient-friendly administration method compared to traditional injectable formulations. These smart capsules are engineered with advanced coatings, controlled-release matrices, or protective excipients, which shield biologics from degradation in the gastrointestinal tract and optimize absorption in targeted intestinal regions, thereby offering a non-invasive alternative to injections and improving patient adherence. For example, in December 2024, Lonza Group AG, a Switzerland-based contract development and manufacturing organization (CDMO), launched a tailored service for smart capsule development, specifically aimed at supporting oral biologics development. This service comprises customized formulation design, selection of protective excipients, and capsule engineering to ensure the stability and targeted release of biologics. It operates by improving the oral bioavailability of sensitive biomolecules while maintaining therapeutic efficacy. Unique aspects encompass end-to-end support from initial concept to preclinical testing, compatibility with multiple biologic modalities (proteins, peptides, nucleic acids), and scalable manufacturing solutions. Applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. The benefits include improved patient convenience, reduced reliance on injections, enhanced compliance, and accelerated development timelines for oral biologic therapies.

Who Are The Companies Operating Across The Oral Biologics & Biosimilars Market Value Chain?

Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Get The Full Oral Biologics & Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Region Holds The Highest Market Share In The Oral Biologics & Biosimilars Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Biologics & Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilars Market 2026, By The Business Research Company

Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Hematology Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795